Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity

Journal of Proteome Research

Volumn 12, Issue 4, 2013, Pages 1723-1731

  Lemeer, Simone ^a   Zörgiebel, Corina ^a   Ruprecht, Benjamin ^a   Kohl, Kristian ^a   Kuster, Bernhard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Munich Center for Integrated Protein Science   (Germany)

Author keywords

ATP ADP probes; drug selectivity; kinase signaling; kinobeads; proteomic profiling

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CELL PROTEIN; NUCLEOTIDE BINDING PROTEIN; PROTEIN TYROSINE KINASE; TOZASERTIB;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; CONTROLLED STUDY; COVALENT BOND; DRUG ANALYSIS; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEOMICS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AURORA KINASES; DRUG EVALUATION, PRECLINICAL; FETAL PROTEINS; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 84875914218     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr301073j     Document Type: Article

References (47)

1. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling Nature 2001, 411 (6835) 355-65
2. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1 (4) 309-15
3. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors Curr. Med. Chem. 1999, 6 (9) 775-805
4. Dar, A. C.; Shokat, K. M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annu. Rev. Biochem. 2011, 80, 769-95
5. Garcia-Echeverria, C.; Traxler, P.; Evans, D. B. ATP site-directed competitive and irreversible inhibitors of protein kinases Med. Res. Rev. 2000, 20 (1) 28-57
6. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update Biochem. J. 2003, 371 (Pt 1) 199-204
7. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351 (Pt 1) 95-105
8. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1039-45
9. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1046-51
10. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-32
11. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 2007, 25 (9) 1035-44
12. Shi, Z.; Resing, K. A.; Ahn, N. G. Networks for the allosteric control of protein kinases Curr. Opin. Struct. Biol. 2006, 16 (6) 686-92
13. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation Mol. Cell 2004, 15 (5) 661-75
14. Frye, S. V.; Johnson, G. L. Inhibitors paradoxically prime kinases Nat. Chem. Biol. 2009, 5 (7) 448-9
15. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. J.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 2010, 464 (7287) 431-5
16. Schirle, M.; Bantscheff, M.; Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery Chem. Biol. 2012, 19 (1) 72-84
17. Wissing, J.; Jansch, L.; Nimtz, M.; Dieterich, G.; Hornberger, R.; Keri, G.; Wehland, J.; Daub, H. Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry Mol. Cell. Proteomics 2007, 6 (3) 537-47
18. Brehmer, D.; Greff, Z.; Godl, K.; Blencke, S.; Kurtenbach, A.; Weber, M.; Muller, S.; Klebl, B.; Cotten, M.; Keri, G.; Wissing, J.; Daub, H. Cellular targets of gefitinib Cancer Res. 2005, 65 (2) 379-82
19. Urbaniak, M. D.; Mathieson, T.; Bantscheff, M.; Eberhard, D.; Grimaldi, R.; Miranda-Saavedra, D.; Wyatt, P.; Ferguson, M. A.; Frearson, J.; Drewes, G. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei ACS Chem. Biol. 2012, 7 (11) 1858-65
20. Godl, K.; Wissing, J.; Kurtenbach, A.; Habenberger, P.; Blencke, S.; Gutbrod, H.; Salassidis, K.; Stein-Gerlach, M.; Missio, A.; Cotten, M.; Daub, H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (26) 15434-9
21. Godl, K.; Gruss, O. J.; Eickhoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z.; Keri, G.; Muller, S.; Cotten, M.; Ullrich, A.; Daub, H. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling Cancer Res. 2005, 65 (15) 6919-26
22. Sharma, K.; Weber, C.; Bairlein, M.; Greff, Z.; Keri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 2009, 6 (10) 741-4
23. Ranjitkar, P.; Perera, B. G.; Swaney, D. L.; Hari, S. B.; Larson, E. T.; Krishnamurty, R.; Merritt, E. A.; Villen, J.; Maly, D. J. Affinity-based probes based on type II kinase inhibitors J. Am. Chem. Soc. 2012, 134 (46) 19017-25
24. Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; Nomanbhoy, T. K.; Wu, M.; Weissig, H.; Aban, A.; Chun, D.; Tanner, S.; Kozarich, J. W. Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 2007, 46 (2) 350-8
25. Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J. D.; Gray, N. S.; Kozarich, J. W. In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 2011, 18 (6) 699-710
26. Carrera, A. C.; Alexandrov, K.; Roberts, T. M. The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (2) 442-6
27. Xu, B.; English, J. M.; Wilsbacher, J. L.; Stippec, S.; Goldsmith, E. J.; Cobb, M. H. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II J. Biol. Chem. 2000, 275 (22) 16795-801
28. Kruse, U.; Pallasch, C. P.; Bantscheff, M.; Eberhard, D.; Frenzel, L.; Ghidelli, S.; Maier, S. K.; Werner, T.; Wendtner, C. M.; Drewes, G. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells Leukemia 2011, 25 (1) 89-100
29. Wu, Z.; Doondeea, J. B.; Gholami, A. M.; Janning, M. C.; Lemeer, S.; Kramer, K.; Eccles, S. A.; Gollin, S. M.; Grenman, R.; Walch, A.; Feller, S. M.; Kuster, B. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer Mol. Cell. Proteomics 2011, 10 (12 M111.011635
30. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 2008, 26 (12) 1367-72
31. Saraste, M.; Sibbald, P. R.; Wittinghofer, A. The P-loop - a common motif in ATP- and GTP-binding proteins Trends Biochem. Sci. 1990, 15 (11) 430-4
32. Inamdar, K. V.; O'Brien, S.; Sen, S.; Keating, M.; Nguyen, M. H.; Wang, X.; Fernandez, M.; Thomazy, V.; Medeiros, L. J.; Bueso-Ramos, C. E. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia Mod. Pathol. 2008, 21 (12) 1428-35
33. Ochi, T.; Fujiwara, H.; Suemori, K.; Azuma, T.; Yakushijin, Y.; Hato, T.; Kuzushima, K.; Yasukawa, M. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia Blood 2009, 113 (1) 66-74
34. Green, M. R.; Woolery, J. E.; Mahadevan, D. Update on Aurora kinase targeted therapeutics in oncology Expert Opin. Drug Discovery 2011, 6 (3) 291-307
35. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat. Med. 2004, 10 (3) 262-7
36. Gizatullin, F.; Yao, Y.; Kung, V.; Harding, M. W.; Loda, M.; Shapiro, G. I. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function Cancer Res. 2006, 66 (15) 7668-77
37. Tyler, R. K.; Shpiro, N.; Marquez, R.; Eyers, P. A. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells Cell Cycle 2007, 6 (22) 2846-54
38. Giles, F. J.; Cortes, J.; Jones, D.; Bergstrom, D.; Kantarjian, H.; Freedman, S. J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation Blood 2007, 109 (2) 500-2
39. Salah, E.; Ugochukwu, E.; Barr, A. J.; von Delft, F.; Knapp, S.; Elkins, J. M. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class J. Med. Chem. 2011, 54 (7) 2359-67
40. Fei, F.; Stoddart, S.; Groffen, J.; Heisterkamp, N. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias Mol. Cancer Ther. 2010, 9 (5) 1318-27
41. Young, M. A.; Shah, N. P.; Chao, L. H.; Seeliger, M.; Milanov, Z. V.; Biggs, W. H., III; Treiber, D. K.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J.; Sawyers, C. L.; Kuriyan, J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680 Cancer Res. 2006, 66 (2) 1007-14
42. Cheetham, G. M.; Charlton, P. A.; Golec, J. M.; Pollard, J. R. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680 Cancer Lett. 2007, 251 (2) 323-9
43. Winter, G. E.; Rix, U.; Lissat, A.; Stukalov, A.; Mullner, M. K.; Bennett, K. L.; Colinge, J.; Nijman, S. M.; Kubicek, S.; Kovar, H.; Kontny, U.; Superti-Furga, G. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B Mol. Cancer Ther. 2011, 10 (10) 1846-56
44. Lozzio, C. B.; Lozzio, B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome Blood 1975, 45 (3) 321-34
45. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors Chem. Biol. 2005, 12 (6) 621-37
46. Becher, I.; Savitski, M. M.; Savitski, M. F.; Hopf, C.; Bantscheff, M.; Drewes, G. Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP ACS Chem. Biol. 2013, 8 (3) 599-607
47. Jackson, A. P.; Flett, A.; Smythe, C.; Hufton, L.; Wettey, F. R.; Smythe, E. Clathrin promotes incorporation of cargo into coated pits by activation of the AP2 adaptor micro2 kinase J. Cell Biol. 2003, 163 (2) 231-6